Allstate Corp Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Allstate Corp bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 3,195 shares of the biopharmaceutical company's stock, valued at approximately $2,276,000.

Several other institutional investors have also recently bought and sold shares of the company. Larson Financial Group LLC lifted its position in shares of Regeneron Pharmaceuticals by 127.3% in the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 28 shares in the last quarter. Independent Advisor Alliance acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $231,000. D.A. Davidson & CO. lifted its position in Regeneron Pharmaceuticals by 5.1% during the 3rd quarter. D.A. Davidson & CO. now owns 821 shares of the biopharmaceutical company's stock worth $863,000 after buying an additional 40 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $151,000. Finally, Public Sector Pension Investment Board boosted its stake in shares of Regeneron Pharmaceuticals by 13.0% during the 3rd quarter. Public Sector Pension Investment Board now owns 4,341 shares of the biopharmaceutical company's stock worth $4,563,000 after buying an additional 500 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

REGN has been the topic of several analyst reports. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. TD Cowen decreased their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research note on Tuesday, February 4th. Bank of America reiterated an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Finally, Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $966.88.

Remove Ads

Regeneron Pharmaceuticals Trading Down 1.2 %

NASDAQ:REGN traded down $7.26 during trading hours on Thursday, hitting $618.34. The company had a trading volume of 230,599 shares, compared to its average volume of 678,029. The stock has a 50-day moving average price of $680.43 and a 200 day moving average price of $786.93. The company has a market capitalization of $67.60 billion, a PE ratio of 16.15, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 52 week low of $605.56 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $11.86 earnings per share. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.57%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.